Summary In this session, Gordan Lauc (Genos Glyco & GlycanAge) and Vadim Gladyshev (Harvard), gave their point of view on biomarkers & aging clocks development. Gordan Lauc went through the interesting glycomic data they recently and insights it generated about aging and menopause, exceptional predictive capability of glycans for hypertension, and much more. Vadim Gladyshev… Continue reading Biomarker & Aging Clock Development | Vadim Gladyshev, Harvard, Gordan Lauc, GlycanAge
Summary In this session, Alex Zhavoronkov, CEO and Founder of Insilico Medicine and Deep Longevity, offered his roadmap for what he calls Longevity as a Service. He explained the approach Deep Longevity and Young.ai are taking, the various clocks and machine learning methods they are using, the necessity for physician education and coordinated building of… Continue reading Longevity as a Service: AI & Aging Clocks | Alex Zhavoronkov, Deep Longevity & Insilico Medicine
Summary In this session, Dylan Livingston, Founder and Executive Director at The Alliance for Longevity Initiatives, introduced the first 501(c)(4) nonprofit organization focused on advocating for government-sponsored initiatives and policies to increase healthy human lifespan in the US. He went over the reasons why it was needed and teased the first draft of the action… Continue reading Dylan Livingston | ALARMA (America’s Longevity, Aging and Regenerative Medicine Association)
Summary In this session, Greg Fahy, Co-Founder of Intervene Immune and Principal Investigator of the TRIIM and TRIIM-X clinical trials, offered a sneak peek on some preliminary data from the TRIIM-X clinical trial along with updates about its development, progress and conditions of the enrollment, as well as optimistically looking first preliminary results. Following discussion… Continue reading Greg Fahy, Intervene Immune | Thymus Rejuvenation Progress Update
Summary In this session, Christopher Leptak, the Director New Drug’s Regulatory Science Program Office in the FDA’s Center for Drug Evaluation and Research, elucidated how is FDA approaching biomarkers specifically for drug development, what is actually considered a biomarker and wha needs to happen for a new biomarker to be used. Apart from valuable tips… Continue reading Biomarkers and Drug Development: Regulatory Perspective | Christopher Leptak
Summary In this session, James Peyer, the CEO and founder of Cambrian Biopharma, shared his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a DisCo model and why it will most likely replace single asset biotech companies model, and… Continue reading James Peyer | Cambrian Bio: How to Fund and Build Geroprotectors
Summary In this session, Ronald Kohanski, the Director of Division of Aging Biology at the National Institute on Aging, presented his ideas and suggestions for a way forward from an NIA perspective. He covered many different areas in the field, starting with an overview of metrics and indices the field is using to track health,… Continue reading Promising Aging Approaches from an NIA Perspective | Ronald Kohanski, National Institute on Aging
Summary In this session, James Kirkland from Mayo Clinic gave a comprehensive overview of the current state of research about senescent cells and senolytic clinical trials. He provided nuanced insights into how senescent cells become senescent, how they work, what kind of functions can they play, and much more. He also went through 15 clinical… Continue reading Clinical Trials & Senolytics | Dr. James Kirkland, Mayo Clinic
Summary In this session, Jean Hebert from the Albert Einstein School of Medicine introduced the idea of brain tissue replacement as a necessary strategy for the long-term defeat of aging. He went through the history of the field and research so far and presented a case for pursuing this approach further based on the available… Continue reading Brain Cell Replacement to Beat Aging | Jean M. Hebert, Albert Einstein School of Medicine
Summary In this session, Brain Kennedy from Buck Institute presented his assessment of the state of aging research in academia and the non incentivized academic research that could dramatically advance progress. After that, Lynne Cox introduced two progress opportunities she identified – new drug discovery approaches focusing on polypharmacology, and in silico systems modelling of… Continue reading Academic blindspots | B. Kennedy, Buck Institute, J. Deelen, Max Planck Institute, L Cox, Oxford Uni
